Results 11 to 20 of about 224,807 (304)
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer [PDF]
Background Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen. The p53 tumor suppressor controls a major
Packman Kathryn +6 more
doaj +2 more sources
Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
PurposeSubstantial evidence indicates that men with prostate cancer are at an increased risk for cardiovascular disease, and medical and surgical androgen deprivation therapy is associated with further increased cardiovascular risk. There are conflicting
Laurence Klotz +3 more
doaj +2 more sources
Conformational dynamics of androgen receptors bound to agonists and antagonists [PDF]
The androgen receptor (AR) is critical in the progression of prostate cancer (PCa). Small molecule antagonists that bind to the ligand binding domain (LBD) of the AR have been successful in treating PCa.
Hyo Jin Gim +3 more
doaj +2 more sources
Androgen deprivation therapy and side effects: are GnRH antagonists safer?
Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and antagonists is the mainstay of advanced prostate cancer treatment. Both drug classes decrease levels of luteinizing hormone and follicle-stimulating hormones (FSH),
Stephen J Freedland +1 more
doaj +2 more sources
Background Previous studies hypothesized that androgen deprivation therapy (ADT) may reduce severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infectivity.
Mateus Bringel Oliveira Duarte +3 more
doaj +1 more source
Simulating androgen receptor selection in designer yeast
Androgen receptor (AR) mutation is closely associated with prostate cancer (PCa) and is one of the mechanisms of resistance to PCa therapies such as AR antagonists. Although sequencing technologies like next-generation sequencing (NGS) contributes to the
Haoran Zhang +8 more
doaj +1 more source
Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
Prostate cancer is a major health issue in western countries and is the second leading cause of cancer death in American men. Prostate cancer depends on the androgen receptor (AR), a transcriptional factor critical for prostate cancer growth and ...
Jian Huang, Biyun Lin, Benyi Li
doaj +1 more source
Therapeutic potential of TRPM8 antagonists in prostate cancer
Transient receptor potential melastatin-8 (TRPM8) represents an emerging target in prostate cancer, although its mechanism of action remains unclear.
Marzia Di Donato +8 more
doaj +1 more source
The epigenetic function of androgen receptor in prostate cancer progression
Androgen and androgen deprivation (castration) therapies, including androgen receptor antagonists, are clinically used to treat patients with prostate cancer.
Takahiro Sawada +9 more
doaj +1 more source
Prostate cancer is one of the malignant tumors and the second most common malignant tumor in men. Clinically used androgen receptor (AR)–targeted drugs can antagonize androgen and inhibit tumor growth, but these drugs can cause serious resistance ...
Yueheng Qi +5 more
doaj +1 more source

